Cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors (Ribociclib) are new-generation drugs that have been used recently in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer. Recent studies have shown that the use of CDK 4/6 inhibitors significantly improves the outcomes of these patients. The most common side effects of CDK 4/6 inhibitors are hematological toxicity, gastrointestinal side effects, and fatigue. Vitiligo-like lesions are a rare side-effect of these drugs. CDK 4/6 inhibitors can inhibit cell division or cause premature cell death by acting on the melanocyte cell cycle. Vitiligo-like lesions are not a life-threatening side effect. However, it significantly affects the quality of life and disrupts the patient’s compliance with treatment. Hence, we aim to present a case of recurrence of breast cancer that was treated with ribociclib and developed vitiligo-like lesions after treatment. Considering the increasing use of this medication and the social stigma associated with vitiligo, it is crucial to be aware of this adverse effect and counsel the patients before starting the therapy.
Mahajan et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: